API
CYTK icon

Advisor Partners II’s Cytokinetics CYTK Stock Holding History

Advisor Partners II’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,156
Closed -$201K – 944
2022
Q3 		$201K Buy
+4,156
New +$200K 0.02% 763

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Advisor Partners II's CYTK Position: Q4 2022 in Review

Advisor Partners II sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 4,156 shares — an estimated $201K sold.

Advisor Partners II first reported a position in CYTK in Q3 2022 and held it in 1 quarter. The position peaked at $201K in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

  • Advisor Partners II reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
  • Advisor Partners II sold 4,156 Cytokinetics shares in Q4 2022, an estimated $201K.
  • Advisor Partners II first reported a position in Cytokinetics in Q3 2022 and held it in 1 quarter.
  • Advisor Partners II's Cytokinetics position peaked at $201K in Q3 2022.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Advisor Partners II's 13F filing for Q4 2022, filed 14 Feb 2023.